TB-500 vs Tb-4: Literature and Handling Compared
TB-500 and Tb-4 are routinely cross-referenced by researchers scoping a literature review. The two records are not equivalent.
Side-by-side research profile
| Parameter | TB-500 | Tb-4 |
|---|---|---|
| PubMed indexed records | 26 | 320 |
| Registered studies (ClinicalTrials.gov) | 1 | 4 |
| Literature depth | Emerging | Moderate |
| Handling class | Lyophilised powder | Lyophilised powder |
| Designation | Research use only | Research use only |
Compound profiles
TB-500 in the indexed record
The literature on TB-500 is a limited body of work: 26 PubMed-indexed records, alongside 1 registered studies on ClinicalTrials.gov.
Recent indexed work appears in Am J Sports Med, Front Aging, J Am Acad Orthop Surg Glob Res Rev, spanning 2024–2026.
- Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions — J Am Acad Orthop Surg Glob Res Rev, 2026. PMID: 41490200
- Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians — Am J Sports Med, 2026. PMID: 41476424
- Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro — J Chromatogr B Analyt Technol Biomed Life Sci, 2024. PMID: 38382158
- Peptide Supplements and Their Therapeutic Applications in Sports Medicine — Am J Sports Med, 2026. PMID: 42578445
Tb-4 in the indexed record
Indexed output for Tb-4 stands at 320 records, a moderate literature, alongside 4 registered studies on ClinicalTrials.gov.
Journals represented in the current index include Am J Sports Med, Dalton Trans, Inorg Chem, spanning 2019–2026.
- Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians — Am J Sports Med, 2026. PMID: 41476424
- Molecular Complex of Tb in the +4 Oxidation State — J Am Chem Soc, 2019. PMID: 31194529
- Tb(HSO(4))(SO(4)) – a green emitting hydrogensulfate sulfate with second harmonic generation response — Dalton Trans, 2019. PMID: 31633142
- Precisely Assembling a CoO Cocatalyst onto Tb(4)O(7)/CN and Pt-Tb(4)O(7)/CN for Promoting Photocatalytic Overall Water Splitting — Inorg Chem, 2024. PMID: 38652804
How the literature differs
The indexed record is not symmetrical between these two compounds. Tb-4 carries 294 more indexed records than TB-500, which means published methodology, characterisation data and replication attempts are more readily located for Tb-4. For a researcher planning a literature review, that asymmetry usually determines which compound has established reference protocols and which requires primary-source work.
Registered study counts (1 vs 4) track a different signal — formal study registration rather than published output — and the two figures frequently diverge.
Classification and why it matters
TB-500 and Tb-4 sit in different structural classes, and that classification is what determines whether a published protocol for one has any bearing on the other. Peptide research compounds are grouped by sequence length, origin and the receptor families the literature associates with them — not by the outcome a reader might be looking for.
Reading across classes is the most common error in a literature review. A protocol developed for TB-500 describes conditions validated for TB-500: concentration ranges, solvent choice, incubation windows and control selection were all established against that compound. Applying those same conditions to Tb-4 without re-validation produces data that cannot be compared back to the source publication.
Where the two compounds are studied in overlapping models, the published work almost always treats them as separate arms rather than as substitutes. That separation is the useful signal: it indicates the research record does not consider them equivalent.
What the paperwork has to show
A certificate of analysis is only meaningful when it names the lot printed on the vial. Purity by HPLC and identity by mass spectrometry answer two different questions, and a document reporting one is not evidence of the other.
Physical handling notes
Both arrive lyophilised. Standard practice keeps the unopened vial at -20°C, protected from light, and defers reconstitution until the point of use. Solution-phase stability is the limiting factor in most protocols, not powder-phase stability.
Repeated freezing and thawing is the most common avoidable source of degradation.
Selecting between them for a study design
TB-500 and Tb-4 are not interchangeable. They differ in structural class and in the pathways the literature associates with each, so substituting one for the other changes what a model is actually measuring.
Where a protocol cites a specific compound, the cited compound is the one the published result applies to. Where no protocol exists, the compound with the deeper indexed record (Tb-4) generally offers more methodological precedent.
Frequently asked questions
How should these compounds be stored?
Lyophilised material is conventionally stored at -20°C protected from light. Reconstituted solution is far less stable and is held at 2-8°C for short-duration laboratory work only.
Are TB-500 and Tb-4 the same compound?
No. They are structurally distinct research compounds with separate literature records — 26 indexed records for TB-500 and 320 for Tb-4.
What is the regulatory status of these compounds?
Neither is an approved drug. Both are supplied strictly for in-vitro laboratory research and are not intended for human or veterinary consumption.
Related references
- TB-500 — product and lot documentation
- Certificate of analysis & purity testing
- Research reference index
Research use only. The compounds discussed are supplied for in-vitro laboratory research. They are not drugs, are not approved for the diagnosis, treatment, cure or prevention of any condition, and are not intended for human or veterinary consumption.